Novartis India
NOVARTIND · Retail > Trading · Chairman: C Snook · MD: Sanjay Murdeshwar · Listing date: Nov. 9, 2000 · Employees: 539 · Mumbai · http://www.novartis.in

Stock Price vs Company Growth
1d
1.3%
1w
3.4%
1m
30.2%
3m
34.9%
6m
99.4%
1y
121.0%
5y
21.7%
all
21.7%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,935 1.3%
1,387
2,588
Company Overview

Sales
371 Cr
Growth: 0.6%
Profit after Tax
97.8 Cr
Growth: 4.9%
Small Cap
4,778 Cr
P/E: 48.9x
Industry P/E: 27.0x
Fundamentals

Sales (Cr) ₹ 371
Growth 0.6%
EBITDA 27.5%
P/S 12.9x
Dividend 2.4%
P/E 48.9x
Book Value ₹ 344
PEG Ratio 88.6x
ROE 11.6%
P/B 5.7x
Shareholding Pattern

Institutions
Promoters
Novartis Ag
70.68 %
Others
Atul Limited
1.52 %
Iepf
0.47 %
Llp, Partnership Firm, Directors' Relative
0.14 %
Increase    Decrease    No change
Company Profile Detailed

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.
Investors (8)
Followers (1)